APLS Buyout Under Scrutiny: Shareholder Investigation Questions Fairness of $41 Per Share Biogen Acquisition
Market Chameleon (Tue, 31-Mar 10:28 AM)
Biogen to Acquire Apellis: $5.6 Billion Deal Adds High-Growth Rare Disease and Immunology Medicines to Biogen’s Portfolio
Market Chameleon (Tue, 31-Mar 7:05 AM)
